Ventyx Expands Global Phase 2 Study for VTX2735 and Strengthens Advisory Team Ahead of Key Data Milestones
Market Chameleon (Tue, 2-Dec 8:12 AM)
VTX3232 Shows Landmark Reduction in Cardiovascular Inflammation Without Weight Loss Impact: Ventyx Biosciences Phase 2 Results Explained
Market Chameleon (Thu, 23-Oct 9:53 AM)
VTX3232 Achieves 78% Reduction in hsCRP: Phase 2 Study Spotlights New Path in Cardiovascular Risk
Market Chameleon (Thu, 23-Oct 7:06 AM)
